|
|
|
|
Report on market potential for RNA therapies
Research and Markets (http://www.researchandmarkets.com/research/e45ece/ribonucleic_acid) has announced the addition of the "Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma" report to their offering.Ribonucleic...
|
|
|
Research and Markets: Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma
Research and Markets ( www.researchandmarkets.com/research/e45ece/ribonucleic_acid : ) has announced the addition of the " Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma : " report to their offering.Ribonucleic...
|
|
|
Research and Markets: Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma
Research and Markets (http://www.researchandmarkets.com/research/e45ece/ribonucleic_acid) has announced the addition of the 'Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma' report to their offering.Ribonucleic...
|
|
|
Research and Markets: Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/e45ece/ribonucleic_acid) has announced the addition of the "Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma" report to their...
|
|
|
Research and Markets: Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/6459a9/big_pharmas_key_l) has announced the addition of the 'Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential' report to their...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
OXFORD, England , February 10 /PRNewswire/ -- Glide Pharma, a specialty pharmaceutical company focused on the needle-free administration of solid dose therapeutics and vaccines, today announced that it has completed an oversubscribed GBP2.7 million...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Author : Glide Pharma Category : Press Release News Alerts by Email ( click here ) News | Home OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a specialty pharmaceutical company focused on the needle-free administration of solid...
|
|
|
Research and Markets: Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential
DUBLINResearch and Markets (http://www.researchandmarkets.com/research/6459a9/big_pharmas_key_l) has announced the addition of the "Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential" report to their offering.Big ...
|
|
|
Research and Markets: Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential
DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/6459a9/big_pharmas_key_l) has announced the addition of the "Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential" report to their...
|
|
|
Research and Markets: Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential
DUBLINResearch and Markets (http://www.researchandmarkets.com/research/6459a9/big_pharmas_key_l) has announced the addition of the "Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential" report to their offering.Big ...
|
|
|
Research and Markets: Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); DUBLIN - (Business Wire) Research and Markets (http://www.researchandmarkets.com/research/6459a9/big_pharmas_key_l) has announced the addition of the "Big Pharma's Key Lifecycle Management...
|
|
|
Research and Markets: Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); DUBLIN - (Business Wire) Research and Markets (http://www.researchandmarkets.com/research/e45ece/ribonucleic_acid) has announced the addition of the "" report to their offering.provides insights...
|
|
|
Research and Markets: Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential
DUBLIN - (BUSINESS WIRE) - Research and Markets (http://www.researchandmarkets.com/research/6459a9/big_pharmas_key_l) has announced the addition of the "Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential" report to their...
|
|
|
Research and Markets: Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma
Research and Markets: DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/e45ece/ribonucleic_acid) has announced the addition of the "" report to their offering.provides insights into the unmet needs in the ...
|
|
|
SADIF Analytics releases new summary due diligence report for Hua Han Bio-Pharmaceutical Holdings Ltd
- SADIF-Investment Analytics has applied its StockMarks stock-rating system to Hua Han Bio-Pharmaceutical Holdings Ltd.and produced a report, rating the company's attractiveness to long-term investors. Ilhavo, Portugal 10/02/2010 SADIF Investment...
|
|
|
Research and Markets: Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma
Research and Markets: DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/e45ece/ribonucleic_acid) has announced the addition of the '' report to their offering.provides insights into the unmet needs in the ...
|
|
|
Research and Markets: Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma
Research and Markets: DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/e45ece/ribonucleic_acid) has announced the addition of the '' report to their offering.provides insights into the unmet needs in the ...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development OXFORD, England,...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development OXFORD, England,...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
OXFORD, England The investment follows the recent successful clinical proof-of-concept of Glide Pharma's proprietary solid dose injector, the Glide SDI(R).The clinical study, conducted in 18 subjects with a solid dose formulation of the analgesic...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
5:00 am OXFORD, England The investment follows the recent successful clinical proof-of-concept of Glide Pharma's proprietary solid dose injector, the Glide SDI(R).The clinical study, conducted in 18 subjects with a solid dose formulation of the...
|
|
|
Catalent Lead Sponsor of 2010 Pharma Packaging and Labeling USA Conference
atalent Pharma Solutions, a provider of outsourced clinical, commercial packaging and printing services to the global pharmaceutical and biotechnology industry, is the lead sponsor of the Pharma Packaging and Labeling USA Conference to be held...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a specialty pharmaceutical company focused on the needle-free administration of solid dose therapeutics and vaccines, today announced that it has completed an oversubscribed GBP2.7 million (...
|
